Who Owns Tasigna?
Tasigna (nilotinib) is owned by Novartis, a publicly traded Swiss multinational pharmaceutical company headquartered in Basel, Switzerland (SIX: NOVN, NASDAQ: NVS). Tasigna is Novartis's chronic myeloid leukemia treatment, first approved by the FDA in 2007. The drug's US patent exclusivity expired in January 2024, opening the market to generic nilotinib competition and putting pressure on Tasigna branded sales. The global CML drug market is expected to reach approximately $4.2 billion, with generic competition reshaping the competitive landscape.
Parent Company
Novartis
Founded
2007
Status
Publicly Traded
Headquarters
Basel, Switzerland
Who Owns Tasigna?
- Parent Company: Novartis
- Ownership Type: Wholly owned
- Company Type: Publicly Traded
- Stock Ticker: SIX: NOVN
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Tasigna | Novartis | Wholly owned |
History of Tasigna
- Founded: 2007
- Founders: Novartis (internal development)
Tasigna was developed by Novartis through extensive research into tyrosine kinase inhibition for treating chronic myeloid leukemia. The drug was approved by the FDA in 2007 as a second-line treatment for CML in patients resistant to or intolerant of imatinib. Tasigna represented an important advancement in CML therapy, offering patients an alternative to existing treatments.
The development of Tasigna involved years of research into BCR-ABL tyrosine kinase inhibition. Novartis conducted extensive clinical trials demonstrating the drug's efficacy in achieving complete cytogenetic response in CML patients. Tasigna quickly became one of the most prescribed CML medications globally.
Following its initial approval, Tasigna expanded its clinical use with approvals for first-line treatment of newly diagnosed CML. The drug's proven benefits in achieving rapid and durable responses made it a standard treatment option for CML patients. Tasigna became one of Novartis's most successful oncology products.
In January 2024, Tasigna's US patent exclusivity expired, allowing generic nilotinib manufacturers to enter the market. This patent expiry is expected to significantly impact Tasigna's branded sales in the United States, as generic versions offer the same active ingredient at lower cost. Novartis has faced increasing pressure on Tasigna revenues as a result, with the drug transitioning from a blockbuster product to a mature brand facing generic competition. The drug remains available globally and continues to be used in markets where generics have not yet entered.
About Novartis
What does Novartis own?
Novartis owns a portfolio of innovative prescription medicines across oncology, immunology, cardiovascular, neuroscience, and ophthalmology. Key products include Cosentyx (inflammatory diseases), Entresto (heart failure), Kisqali (breast cancer), Kesimpta (multiple sclerosis), Leqvio (cholesterol), Zolgensma (gene therapy for spinal muscular atrophy), and Kymriah (CAR-T cell therapy). Novartis spun off its Sandoz generics division in 2023 and its Alcon eye care division in 2019.
Is Novartis publicly traded?
Yes, Novartis AG is listed on the SIX Swiss Exchange under ticker NOVN and on NASDAQ under ticker NVS (as American Depositary Receipts). The company has a broad institutional and retail shareholder base with no single controlling shareholder. Major institutional shareholders include Vanguard Group and BlackRock.
Who founded Novartis?
Novartis was formed in 1996 through the merger of Ciba-Geigy and Sandoz, two of Switzerland's oldest pharmaceutical companies. Ciba-Geigy itself was formed through the 1970 merger of Ciba and Geigy, both founded in Basel in the 19th century. Sandoz was founded in 1886 in Basel. The 1996 merger was one of the largest corporate mergers in history at the time, valued at approximately $63 billion.
Where is Novartis headquartered?
Novartis AG is headquartered in Basel, Switzerland. Basel has been the center of the Swiss pharmaceutical industry for more than a century, and Novartis, Roche, and several other major pharmaceutical companies are headquartered in the city. Novartis operates manufacturing and research facilities in Switzerland, the United States, Germany, Spain, Italy, Japan, China, India, Singapore, and Brazil.
How many products does Novartis sell?
Novartis sells dozens of prescription medicines across multiple therapeutic areas. The company's growth portfolio is led by Cosentyx, Entresto, Kisqali, Kesimpta, Leqvio, Zolgensma, and Kymriah. Novartis has a pipeline of more than 150 projects in clinical development across its therapeutic focus areas. The company sells products in more than 140 countries worldwide.
Who owns Novartis?
Novartis AG is publicly traded on the SIX Swiss Exchange and NASDAQ with a broad institutional and retail shareholder base. No single shareholder holds a controlling stake. The Novartis Foundation for Employee Participation holds a significant stake. Major institutional shareholders include Vanguard Group and BlackRock. Vas Narasimhan serves as CEO and Joerg Reinhardt chairs the board.
- Founded: 1996
- Headquarters: Basel, Switzerland
- Company Type: Publicly Traded
- Stock: SIX: NOVN
Where Is Tasigna Made / Based?
- Headquarters: Basel, Switzerland
- Manufacturing / Operations: Switzerland, Germany, United States
Brands Owned by Novartis
- Afinitor - Prescription oncology medication for treating various cancers including renal ce...
- Alcon - Global leader in eye care products and surgical equipment, specializing in conta...
- Cosentyx - Prescription biologic medication for treating autoimmune diseases including psor...
- Exelon - Brand name for rivastigmine, a prescription cholinesterase inhibitor developed b...
- Gilenya - Prescription immunosuppressant medication for treating relapsing-remitting multi...
- Lamisil - Over-the-counter antifungal medication for treating fungal infections including ...
- Lucentis - Prescription biologic medication for treating age-related macular degeneration a...
- Otrivin - Over-the-counter nasal decongestant spray for relieving nasal congestion from co...
- Sandoz - Independent global leader in generic and biosimilar pharmaceuticals, spun off fr...
- Theraflu - Over-the-counter cold and flu relief medication combining multiple active ingred...
- Voltaren - Over-the-counter anti-inflammatory pain relief brand containing diclofenac, owne...
Tasigna Ownership: Pros & Cons
Advantages
- +Effective tyrosine kinase inhibitor for chronic myeloid leukemia
- +Proven efficacy in achieving complete cytogenetic response
- +Available for both first-line and second-line CML treatment
- +Backed by extensive clinical research and safety data
- +Supported by Novartis's research capabilities and pharmaceutical expertise
- +Available globally with established distribution networks
- +Improved survival outcomes for CML patients
Considerations
- -High cost as a prescription oncology medication
- -Requires regular monitoring by healthcare professionals
- -Potential for serious adverse effects including cardiovascular events
- -Not suitable for patients with certain cardiac conditions
- -Requires consistent adherence to treatment regimen
- -Competition from other CML medications
- -Potential for drug interactions with other medications
Frequently Asked Questions About Tasigna
Where to Buy
Disclosure: We may earn commission from purchases
Tasigna on AmazonNovartis Stock Information
Jobs at Novartis
Latest News About Tasigna
Related Articles About Tasigna
View more articles
Pharmaceutical Brand Ownership: A Complete Guide
Who makes your medications? Discover which corporations own the biggest pharmaceutical brands, from Ozempic to Tylenol, and how pharma M&A affects you.
Monthly M&A Roundup: February 2026 Brand Ownership Changes
From Keurig Dr Pepper's planned split to the Netflix-WBD saga, here is every major brand ownership change and deal in February 2026.
The Most Acquired Categories: Tech vs CPG vs Pharma
Which industries see the most brand acquisitions? We compared technology, consumer goods, and pharmaceuticals to find out where the most M&A activity happens and why.